Study drug discontinuation and interruptions
Pyrexia, nausea, pneumonia, dyspnea, pyrexia, headache, sepsis
PLEURAL EFFUSION, SEPSIS, PNEUMONIA
Across all cohorts, 28 (13.6%) patients had AEs that led to discontinuation of the study treatment (dabrafenib or trametinib). The most common AEs leading to study drug discontinuation were nausea (1.5%) and dyspnea, decreased ejection fraction, headache, pleural effusion, pneumonia, pyrexia and sepsis (1.0% each) (Supplementary Table A total of 91 patients (44.2%) and 116 (56.3%) patients had AEs requiring dose reduction and any dose interruption, respectively. Pyrexia (